Anti-Convulsant Drug Valproic Acid in Cancers and in Combination Anti-Cancer Therapeutics

Lichun Sun* and David H Coy

Department of Medicine, Tulane Health Sciences Center, USA

Abstract

The traditional anti-convulsant drug Valproic Acid (VPA) has been found to be involved in suppressing cancer progression while modulating various cancer-associated signaling pathways. In particular, VPA acts either as a Histone Deacetylase (HDAC) inhibitor or a Notch signaling activator in suppressing tumor growth. VPA is less toxic, and by itself, has limited anti-tumor effects. Thus, VPA has been used as an adjuvant in combination with a variety of other anti-cancer agents for many types of cancers. These combination strategies display potential applications in cancer treatments. In particular, VPA could up-regulate certain G Protein-Coupled Receptors (GPCRs) in some cancer cells. Some of these GPCRs are highly expressed naturally in many cancer cells and these characteristics have been applied towards novel enhanced combination therapeutics with VPA and specific receptor-targeted cytotoxic peptide-drug conjugates.

Keywords: Valproic acid (VPA); Combination therapeutics; Receptor-targeted; Peptide-drug conjugate

Introduction

Valproic Acid (VPA) is a branched short-chain chemical molecule (C₈H₁₆O₂) (Figure 1) and has been used as an anti-convulsant drug for several decades [1,2]. In recent years, VPA has been investigated further for its potential application in cancer treatments [3-6] since its initial use in treatment of pediatric malignant gliomas [2]. Due to its less potent anti-cancer efficacy alone, VPA is more frequently used as an adjuvant in combination with other anti-cancer therapeutic agents [3,4,7,8]. The combination therapy displays more synergistic anti-cancer effects than each individual agent alone. In particular, VPA has been found to enhance the expression of certain G Protein-Coupled Receptors (GPCRs) in certain cancers [9,10]. These characteristics could be applied in a combination treatment using VPA with receptor-specific cytotoxic conjugates. In this combination therapy, VPA plays a critical dual role via acting as a direct tumor suppressor and an indirect tumor-suppressing enhancer of receptor-specific cytotoxic conjugates.

VPA in anti-cancer treatment

VPA has been widely investigated for its anti-cancer efficacy in many cancers, including cervical cancer, prostate cancer, neuroblastoma, Medullary Thyroid Cancer (MTC), myeloma, colon cancer, glioma, leukemia, breast cancer, lung cancer, bladder cancer, melanoma, leukemia, glioblastoma, Renal Cell Cancer (RCC), esophageal squamous cell cancer, endometrial stromal sarcoma, osteosarcoma, Hepatocellular Cancer (HCC), gastrointestinal carcinoid, phaeochromocytoma, mesothelioma, pancreatic cancer, head/neck squamous cell cancer, ovarian cancer, myeloma and cholangiocarcinoma [7,8,11-13]. VPA displays its effects in multiple cancer cell functions such as DNA damage, cell cycle arrest, cell apoptosis, differentiation, proliferation, and senescence as seen in serial in vitro studies. VPA is also involved with various associated signaling pathways [2,11,14]. Using serial in vivo studies, VPA is also found to suppress tumor growth, tumor angiogenesis and tumor metastasis [2,15,16]. VPA alone is currently under clinical evaluation in many cancers [7,8] but VPA has very limited effect due to its weak anti-cancer efficacy. Conversely, VPA has less toxic side effects and is more frequently used as an ideal adjuvant agent in combination with many other anti-cancer cytotoxic therapeutic agents. These combined therapeutics display synergistic anti-cancer effects discussed below.

VPA-mediated anti-cancer molecular signaling

VPA's anti-cancer effect is involved in multiple signaling pathways such as the Wnt signaling pathway, PI3K/AKT pathway, p21WAF1/CDKN1A pathway and MAPK/ERK [2,7,11,12,17-19]. VPA is believed most likely to act as a Histone Deacetylase (HDAC) inhibitor in mediating histone deacetylation and subsequent tumor suppression, along with its involvement in other signaling pathways [2,20]. Another critical signaling pathway, Notch signaling, is also believed to be involved in VPA-mediated tumor suppression [21-24]. It is not clear whether or how these two signaling pathways correlate or interact with each other in VPA-treated cancer cells. VPA could affect histone acetylation/deacetylation in many cases. VPA could also simultaneously modulate both signaling pathways in others. For instance, VPA up-regulates Notch1 and enhances acetylation of histone H3 in cervical cancer cells [9,25] and in Neuroblastoma (NB) cells [26]. However,

*Corresponding author: Lichun Sun, Professor, Department of Medicine, Peptide Research Laboratories, Tulane Health Sciences Center. New Orleans, LA 70112-2699, USA, Tel: 504-988-1179; Fax: 504-988-3586; E-mail: lsun@tulane.edu

Received January 02, 2014; Accepted January 22, 2014; Published January 27, 2014

Citation: Sun L, Coy DH (2014) Anti-Convulsant Drug Valproic Acid in Cancers and in Combination Anti-Cancer Therapeutics. Mod Chem appl 2: 118. doi:10.4172/2329-6798.1000118

Copyright: © 2014 Sun L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
VPA was found to suppress cell growth directly via the involvement of Notch signaling in others such as follicular thyroid cancer cells and pancreatic carcinoid cells [21,27]. We also observed that VPA upregulates Notch1 expression and cell growth arrest in carcinoid cells, without the involvement of HDAC3 and HDAC4 (data not shown).

VPA acts as a histone deacetylase (HDAC) inhibitor

HDACs deacetylate histones via removing acetyl groups from lysine residues of histones. Histone deacetylation could block gene transcription, initiate cancer progression and lead to drug resistance [28,29]. VPA could induce HDAC inhibition, histone deacetylation and hyperacetylation accumulation, and reverse HDAC-mediated transcriptional repression and subsequently mediate various cell functions such as cell differentiation and cell apoptosis [28,30-32]. In 2001, Klein and co-workers identified that VPA acted as a HDAC inhibitor [19] via targeting HDACs including HDAC 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 in the four major HDAC classes with 18 different HDAC members [28,32,33]. In most cases, VPA was reported mainly to induce the acetylation of histones H3 and H4. VPA has been identified in mediating histone acetylation/deacetylation and resulting in tumor suppression in many different cancer cells such as colon cancer cells, glioblastoma cells, neuroblastoma cells, cervical cancer cells, glioma cells, leukemia cells, teratocarcinoma cells, prostate cancer cells, bladder cancers cells and endometrial stromal sarcoma cells [7,8,30]. Besides its use in anti-convulsant treatments, the characteristies of VPA in decreasing deacetylation and increasing acetylation could be used as a strategy for treatment of cancers. In some cases, however, VPA does not always act as a HDAC inhibitor and instead acts as a HDAC activator to upregulate HDAC activity in glioma C6 cells [10] and also to reduce histone H3 expression but not to affect H3 acetylation in renal cell cancer Caki-1 cells [34].

VPA acts as a Notch signaling regulator

Notch signaling plays a critical role in determining cell fates and is involved in cancer progression. Notch signaling can play different roles in different cancers, acting as a tumor suppressor in certain cancers and an oncogene in some others. VPA is involved in regulation of the Notch signaling pathway and the subsequent tumor progression [22,23,26,35,36], playing different roles in regulating Notch signaling in a cancer type-dependent manner. Notch signaling acts as a tumor suppressor in certain NET tumors such as Medullary Thyroid Cancer (MTC) [21,22,37] and certain non-NET tumors such as cervical cancer [23,38-40]. In these cancers, VPA was found to act as a positive Notch1 signaling regulator to subsequently induce tumor suppression. For instance, in NET tumors, VPA could activate Notch1 signaling, regulate the neuroendocrine phenotype with down-regulation of neuroendocrine markers CgA and ASCL1, and further induce growth arrest and cell differentiation in phenochromocytoma cells, MTC cells, SCLC cells and carcinoid cells [21,22,35,36]. In pancreatic carcinoid BON cells, VPA could induce cell growth arrest via modulating Notch1 activation and the subsequent increase in p21 and decrease in ACSL [21]. In non-NET tumors such as thyroid cancer, cervical cancer, and osteosarcoma, Notch1 signaling also plays a tumor-suppressive role [9,23,25,27]. VPA mediates Notch1 upregulation and enhances histone H3 acetylation in cervical cancer Hela cells, with an increase of tumor suppressor p21 in a p53-independent manner [9,25]. In follicular thyroid cancer cells, Notch1 knockdown blocks VPA-induced anti-cell proliferation and reverses VPA-mediated expression of p21 and cyclin D1, indicating VPA induces cell cycle arrest via activating Notch1 signaling [27]. VPA could also act as a negative Notch regulator in certain cancers. Notch signaling is found to play an oncogenic role in Hepatocellular Cancer (HCC) Hep3B cells [41]. In the HCC HuH7 cell line, VPA induced Notch1 down-regulation and caspase-3 up-regulation, with suppression of cell proliferation and tumor growth [24].

VPA in combination with cytotoxic agents

As described above, due to its limited anti-cancer efficacy alone and less toxic side effects, VPA has been more frequently used as an adjuvant agent in combination with other anti-cancer cytotoxic agents. VPA has been used in combination therapies with various other compounds, some of which are FDA-approved market drugs [7,8]. These combination treatments display more anti-cancer effects compared to each alone [9,42,43], with some under clinical investigations [7,8,42]. For instance, VPA was used in combination with the topoisomerase I inhibitors Camptothecin (CPT), its new analog irinotecan (CPT-11) or CPT conjugates for treating many cancers such as breast cancer, hepatocellular cancer, cervical cancer, lymphoma, thyroid cancer, pancreatic carcinoid, osteosarcoma and ovarian cancer, displaying synergistic in vitro anti-proliferative and in vivo anti-tumor effects [7,9,44]. In particular, the VPA/CPT combination is under phase III clinical evaluation for treating patients with treatment-refractory ovarian cancers and recurrent/metastatic cervical cancers [8]. The combination of VPA and All-Trans Retinoic Acid (ATRA), the carboxyl acid form of vitamin A, used to treat acute leukemia was used to treat certain cancers such as cervical cancer, head/neck squamous cell cancer and leukemia and displayed synergistic anti-cancer effects [7,14,45,46]. VPA was also used to treat leukemia and lymphoma in combination with the anti-metabolite clofarabine, cytarabine, AZA, Aza-dC (5-aza-2’-deoxycytidine or decitabine), enzastaurin, rituximab, IFN-alpha, AY4 and CPT conjugates [7-9,47,48]. The combination therapeutics of VPA/ATRA, VPA/AZA and VPA/Aza-dC are under clinical evaluation for treating leukemia [7]. Moreover, VPA in combination was used to treat many more cancers such as neuroblastoma with the COX2-selective inhibitor celecoxib, glioblastoma with the mitotic inhibitor paclitaxel, prostate cancer with rapamycin (mTOR) inhibitor RAD001, cholangiocarcinoma with gemcitabine, glioma with temozolomide, renal cell cancer with AE8788, colorectal cancer with rexinoid I1F, lung cancer with the Ras inhibitor FTS, melanoma with dacarbazine, mesothelioma with lovastatin and doxorubicin, glioblastoma with sorafenib and bortezomib, thyroid cancer with doxorubicin, breast cancer with CPT and tamoxifen as well as neuroblastoma with ellipticine and celecoxib [3,4,7,8,13,34,44,45,49,50]. Many of these combination treatments show synergistic functions and enhanced anti-cancer effects while reducing the toxic side effects in some organs that result from a single specific high-dose drug, or the multi-drug resistance of cancer cells resulting from long-term treatments. VPA, in combination with multiple anti-cancer agents, is currently under clinical investigations for treating various types of cancers [8,51].

VPA in combination with receptor-targeted cytotoxic peptide-drug conjugates

While displaying tumor suppression, VPA was also found to enhance the expression of certain GPCRs in cancer cells. Thus, these unique dual functions displayed by VPA could result in a novel combination therapy of VPA with a receptor-specific cytotoxic conjugate and this combination could enhance the anti-tumor efficacy of the conjugate via increasing its quick internalization. This may display unique and significant advantages compared to the conventional combination therapeutics of VPA and the other agents described above.

VPA acts as a G protein-coupled receptor (GPCR) regulator

GPCRs belong to a large family with nearly 1000 members and...
These findings could provide a novel strategy of receptor-targeted drug delivery vehicles when coupled with anti-cancer drugs and thus have their specific ligands, agonists/antagonists and even even modified long-acting peptide analogs have already been used as drug delivery vehicles by being coupled with various small molecule anti-cancer agents to form cytotoxic peptide-drug conjugates (Figure 3). These new peptide-drug conjugates could target the specific GPCRs on cancer cell surfaces and quickly internalize drugs of interest inside cells [60]. Moreover, these conjugates have been demonstrated capable of improving the non-specific small molecule agent's anti-cancer efficacy while reducing severe toxic side effects and multiple drug resistance [61,62]. For instance, cytotoxic peptide-drug conjugates such as SSTR2-specific cytotoxic conjugates DOX-SST, COL-SST and CPT-SST, and the GRPR-specific cytotoxic conjugates CPT-BN and DOX-BN [61,63] display more effective anti-tumor activity in various tumors [61,62]. The increase of the specific receptor density will accelerate the internalization of these peptide-drug conjugates and further improve the anti-cancer efficacy of drugs.

**Receptor-targeted peptide-drug conjugates**

Modified long-acting peptide analogs have already been used as drug delivery vehicles by being coupled with anti-cancer agents to form cytotoxic peptide-drug conjugates (Figure 3). These new peptide-drug conjugates could target the specific GPCRs on cancer cell surfaces and quickly internalize drugs of interest inside cells [60]. Moreover, these conjugates have been demonstrated capable of improving the non-specific small molecule agent's anti-cancer efficacy while reducing severe toxic side effects and multiple drug resistance [61,62]. For instance, cytotoxic peptide-drug conjugates such as SSTR2-specific cytotoxic conjugates DOX-SST, COL-SST and CPT-SST, and the GRPR-specific cytotoxic conjugates CPT-BN and DOX-BN [61,63] display more effective anti-tumor activity in various tumors [61,62]. The increase of the specific receptor density will accelerate the internalization of these peptide-drug conjugates and further improve the anti-cancer efficacy of drugs.

**VPA in combination with cytotoxic peptide-drug conjugates**

As described above, VPA could function as a tumor suppressor and a receptor activator in the same cancer cells. VPA-induced increase of receptor density could more quickly promote cell internalization of these receptor-targeting conjugates and further enhance their anti-tumor ability. Thus, the combination application of peptide-drug conjugates and VPA may provide great opportunities to improve the anti-tumor efficacy compared to each alone. Indeed, it has been demonstrated that VPA-induced receptor up-regulation could dramatically enhance the anti-cancer efficacy of these receptor-targeted therapeutic agents [9].

Currently, investigators concentrate more interest on peptide-drug conjugates that target GPCRs, like SSTR2 and GRPR, due to these receptors having been identified as highly expressed in many cancer cells. VPA was found to enhance the expression of abundant SSTR2 and GRPR in natural cancer cells such as cervical cancer cells, carcinoid cells, SCLC cells and hepatocellular cancer cells as described above. Thus, a combination therapy with VPA and SSTR2-targeted cytotoxic SST-drug conjugates (such as CPT-SST, DOX-SST, COL-SST), or VPA and GRPR-targeted cytotoxic BN-drug conjugates (such as CPT-BN, DOX-BN, COL-BN) may possibly be applied in treating these cancers. It has been observed that the combination of VPA and the GRPR-targeted CPT-BN conjugate additively suppress in vitro cell proliferation in leukemia MOLT-4, Jurkat cells, osteosarcoma U2OS cells, carcinoid BON cells and CNDT2 cells. We also have observed that the combination of VPA and another SSTR2-targeted CPT-SST conjugate could enhance the cell proliferative suppression in various cancer cells,
including cervical cancer Hela cells, carcinoma BON cells, SCLC DMS53 cells, HCC HTB-52, HB8064 cells, pancreatic cancer CFPAC-1 cells, colon cancer HT-29 cells, ovarian cancer OVCAR8 cells, SKOV3 cells, MTC TT cells, prostate cancer DU-145 cells and PC-3 cells, leukemia MOLT-4 and Jurkat cells [unpublished data]. The in vivo studies further confirm their synergistic suppressive effects on tumor growth [9,43]. For instance, VPA could act as a tumor suppressor and up-regulate the SSTR2 that is highly expressed in cervical cancer Hela cells. Based on this, VPA and the SSTR2-targeted conjugate COL-SST, used at much lower doses, display a much more synergistic effect on cervical cancer Hela tumor growth than did each single one given at higher doses [7,43]. Similar results were also observed with the treatment of VPA and another conjugate CPT-SST in Hela tumors in xenografts [9]. The synergistic effects of VPA and COL-SST, or VPA and CPT-SST were also observed in treating pancreatic carcinoid BON tumors and ovarian cancer OVCAR8 tumors [unpublished data]. These findings suggest that VPA-mediated receptor up-regulation could increase the uptake and anti-tumor efficacy of receptor-targeting conjugates.

Conclusion

VPA has less toxic side effects on patients and also has broad but limited anti-cancer effects on many cancers. Thus, VPA is a potential anti-cancer adjuvant in combination with other anti-cancer agents. In particular, with the characteristics of receptor-expressing enhancement, VPA in combination with receptor-targeted cytotoxic peptide-drug conjugates could be a potential anti-cancer approach.

References

1. Perucca E (2002) Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16: 695-714.
2. Kostrouchova M, Kostrouch Z, Kostrouchova M (2007) Valproic acid, a molecular lead to multiple regulatory pathways. Folia Biol (Praha) 53: 37-49.
3. Cha HY, Lee BS, Kang S, Shin YS, Chang JW, et al. (2013) Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death. Ann Surg Oncol 20 Suppl 3: S716-724.
4. Li Y, Liu T, Ivan C, Huang J, Shen DY, et al. (2013) Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells. Front Oncol 3: 58.
5. Michaelis M, Doerr HW, Cinatl J Jr (2007) Valproic acid as anti-cancer drug. Curr Pharm Des 13: 3378-3393.
6. Blaheta RA, Cinatl J Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 22: 492-511.
7. Sun LC (2013) Valproic acid: pharmacology, mechanisms of action and clinical implications: The novel applications of anticonvulsant drug Valproic acid in cancer therapeutics. Nova Science Publishers, Inc, New York, USA.
8. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, et al. (2008) Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222.
9. Franko-Tobin LG, Mackey LV, Huang W, Song X, Jin B, et al. (2012) Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist 17: 220-232.
10. Castro LM, Gallant M, Niles LP (2005) Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C8 glioma cells. J Neurochem 95: 1227-1236.
11. Witt D, Burfeind P, von Hardenberg S, Opitz L, Salinas-Riester G, et al. (2013) Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Carcinogenesis 34: 1115-1124.
12. Juengel E, Makarevici J, Tsaur I, Bartsch G, Nelson K, et al. (2013) Resistance after chronic administration of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One 8: e53100.
13. Chen Y, Tsai YH, Tseng SH (2011) Combined valproic acid and celecoxib treatment induced synergistic cytotoxicity and apoptosis in neuroblastoma cells. Anticancer Res 31: 2231-2239.
14. Gan CP, Hamid S, Hor SY, Zain RB, Ismail SM, et al. (2012) Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 34: 344-353.
15. Michaelis M, Michaelis UR, Fleming I, Suhai T, Cinatl J, et al. (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-527.
16. Driever PH, Knüpper MM, Cinatl J, Wolff JE (1999) Valproic acid for the treatment of pediatric malignant glioma. KlinPadiat 211: 323-328.
17. Guadalupe DG, Alma CB, Erick CH, Jose DC, Luis GQ, et al. (2012) Effects of valproic acid upon the PI3K/AKT pathway in MCF-7 breast cancer cells. International Research Journal of Pharmacy and Pharmacology 2:153-159.
18. Owens MJ, Nemeroff CB (2003) Pharmacology of valproate. Psychopharmacol Bull 37 Suppl 2: 17-24.
19. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
20. Johannessen CU (2000) Mechanisms of action of valproate: a commentary. Neurochem Int 37: 103-110.
21. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, et al. (2007) Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist 12: 942-951.
22. Adler JT, Hottinger DG, Kuninmialyaan M, Chen H (2009) Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann SurgOncol 16: 481-486.
23. Talora C, Ciaff S, Segatto O, Morrone S, Kim Choi J, et al. (2005) Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res 305: 343-354.
24. Machado MC, Bellodi-Privato M, Kubrusly MS, Molan NA, Tharciaco T Jr, et al. (2011) Valproic acid inhibits human hepatocellular cancer cells growth in vitro and vivo. J ExpTherOncol 9: 85-92.
25. Sami S, Höl N, Xu HM, Shen Z, Huang X (2008) Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 144: 357-362.
26. Stockhausen MT, Sjölund J, Manetopoulous C, Axelsson H (2005) Effects of the histone deacetylase inhibitor valproic acid on Notch signaling in human neuroblastoma cells. Br J Cancer 92: 751-759.
27. Xiao X, Ning L, Chen H (2009) Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol Cancer Ther 8: 350-356.
28. Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J HematolOncol 3: 5.
29. David G, Alland L, Hong SH, Wong CW, DePinho RA, et al. (1998) Histone deacetylase is associated with mdm3a mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 16: 2549-2556.
30. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6699-6678.
31. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, et al. (2006) Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191: 465-472.
32. Gottlicher M (2004) Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83 Suppl 1: S91-92.
33. Chateaustevius S, Morceau P, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010.
34. Juengel E, Engler J, Mickuckyte A, Jones J, Hudak L, et al. (2010) Effects of combined valproic acid and the epidermal growth factorvascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int 105: 549-557.
35. Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR, et al. (2008) Valproic acid activates Notch1 signaling and induces apoptosis in medulillary thyroid cancer cells. Ann Surg 247: 1038-1040.
36. Adler JT, Hottinger DG, Kuninmialyaan M, Chen H (2008) Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery 144: 956-961.
37. Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, et al. (2011) A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist 16: 835-843.
45. Scherpereel A, Berghmans T, Laffitte JJ, Colinet B, Richez M, et al. (2011) Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 37: 129-135.

46. Marks PA (2010) Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. BiochimBiophysActa 1799: 717-725.

47. Kim B, Rincón Castro LM, Jawed S, Niles LP (2008) Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor. HDAC and MeCP2 mRNA expression in C6 glioma cells. Eur J Pharmacol 589: 45-48.

48. Jawed S, Kim B, Ottenhof T, Brown GM, Werskuijt ES, et al. (2007) Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 560: 17-22.

49. Engl T, Reja B, Blumenberg C, Müller I, Ringel EM, et al. (2006) Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 78: 1784-1793.

50. Gul H, Marquez-Curtis LA, Jahroudi N, Larratt LM, Janowska-Wieczorek A (2010) Valproic acid exerts differential effects on CXCR4 expression in leukemic cells. Leuk Res 34: 237-242.

51. Chen G, Manji HK, Wright CB, Hawver DB, Potter WZ (1996) Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 15: 271-280.

52. Sullivan NR, Burke T, Siafaka-Kapadai A, Javors M, Hensler JG (2004) Effect of valproic acid on serotinin-2A receptor signaling in C6 glioma cells. J Neurochem 90: 1269-1275.

53. Schwarz K, Romanski A, Puccetti E, Wietbrauk S, Vogel A, et al. (2011) The deacetylase inhibitor LAQ824 induces notch signalling in haematopoietic progenitor cells. Leuk Res 35: 119-125.

54. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24: 389-427.

55. Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, et al. (2006) Prostate specific antigen (PSA) as a marker of prostate cancer progression. Oncotarget 1: 34-42.

56. van Nijen N, Verhagen J, van der Wouden H, van Trijp T, Duijvestijn WB, et al. (2004) Prostate specific antigen as a marker of prostate cancer progression. Oncotarget 1: 33-34.

57. Xie C, Edwards H, Lograsso SB, Buck SA, Matherly LH, et al. (2012) Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatr Blood Cancer 59: 1245-1251.

58. Xie C, Edwards H, Xu X, Zhou H, Buck SA, et al. (2010) Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 16: 5499-5510.

59. van Nijen N, Verhagen J, van der Wouden H, van Trijp T, Duijvestijn WB, et al. (2004) Prostate specific antigen as a marker of prostate cancer progression. Oncotarget 1: 33-34.

60. Sun L, Luo J, Mackey LV, Morris LM, Franko-Tobin LG, et al. (2011) Investigation of cancer cell lines for peptide receptor-targeted drug development. J Drug Target 19: 719-730.

61. Sun LC, Coy DH (2011) Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 8: 2-10.

62. Nagy A, Schally AV (2005) Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a “smarter” chemotherapy. Curr Pharm Des 11: 1167-1180.

63. Sun L, Morris LM, Luo J, Mackey LV, Leslie JS, et al. (2011) Application of human pancreatic carcinoid BON cells for receptor-targeted drug development. J Drug Target 19: 686-674.